<DOC>
	<DOCNO>NCT01323192</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy JNS001 titrate daily dos 18 72 mg adult attention-deficit hyperactivity disorder ( ADHD ) relative placebo .</brief_summary>
	<brief_title>An Efficacy Safety Study JNS001 Adults With Attention-Deficit Hyperactivity Disorder</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double-blind ( DB , neither physician patient know name assign drug ) , multicenter , placebo-controlled , parallel group ( group patient treat time ) , dose-titration study . This study consist screen period , DB phase ( titration period efficacy assessment period ) , post-study phase . The study include 1 2-week screening period wash-out prohibit drug , screen eligibility . Eligible patient randomly assign receive JNS001 placebo ratio 1:1 . The study also include 4-week titration period . Patients titrate start dose 18 mg/day match placebo 7 day ( +/- 2 day ) , continue weekly ( +/- 2 day ) increment 18 mg individualize dose achieve . Once individualized dose achieve , patient remain dose rest titration period far tolerable . Doses tapered titration period study , dose up-titrated rest period . The 4-week titration period follow 4-week efficacy assessment period . The post-study phase collection additional safety data schedule 1 week patient 's final study treatment . The study drug administer water daily morning dose 18 mg , 36 mg , 54 mg , 72 mg per day match placebo . The study treatment period 8 week ( titration period 4 week efficacy assessment period 4 week ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Patients meet criterion ADHD ( predominantly inattentive type [ 314.00 ] , predominantly hyperactiveimpulsive type [ 314.01 ] , combine type [ 314.01 ] ) DSMIVTR present childhood , base Conners ' Adult ADHD Diagnostic Interview DSMIV ( CAADID ) screen DSMIV Total ADHD Symptoms score ( 18 item ) CAARSO : SV score = 24 determine investigator coinvestigator baseline Healthy basis physical examination , medical history , vital sign , 12lead ECG clinical laboratory test perform screen Women childbearing potential must negative urine pregnancy test screening Patients ( legallyacceptable representative patient 18 19 year age ) must sign informed consent form ( ICF ) , indicate understand purpose procedure require study willing participate study . Presence history comorbid psychiatric diagnosis per DSMIVTR criterion bipolar I disorder , schizophrenia , schizoaffective disorder , severe obsessive compulsive disorder Presence comorbid psychiatric diagnosis per DSMIVTR criterion pervasive developmental disorder ( include autistic disorder Asperger 's disorder ) , suicidality , diagnosis judgment investigator coinvestigator would exclude patient study Presence motor tic , history Tourette 's disorder , family history Tourette 's disorder Known suspect mental retardation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Concerta</keyword>
	<keyword>Adults</keyword>
	<keyword>Attention-Deficit/Hyperactivity Disorder</keyword>
	<keyword>ADHD</keyword>
	<keyword>Methylphenidate hydrochloride</keyword>
</DOC>